This exciting program is designed to efficiently advance early stage projects, that have the potential to benefit patients, to proof of concept studies. Sanders TDI contributes medicinal chemistry and drug development capabilities that complement the deep scientific expertise already available in our research community.
The recipients of Sanders TDI support will be selected by a Request for Proposal (RFP) process. To select the most promising projects in the most unbiased manner possible, Sanders TDI draws upon a scientific advisory board (SAB) comprised of recognized scientific and thought leaders drawn from the biopharmaceutical industry, the venture capital community, and the faculty of WCMC, RU and MSKCC (for a list of members please see the About Sanders TDI web page: https://www.tritdi.org/leadership/). The SAB utilizes well-established, stringent criteria to select the most competitive and transformational projects for execution. The SAB also helps to oversee and assess progress of the selected projects, which are milestone-driven and designed to reach specified value-inflection points.
The project application is a three-step process:
- Submission of a letter of intent (LOI) that includes a basic description of the project, describes the unmet medical need, and provides a scientific rationale the project. The Letter of Intent is due Thursday, Feb 13, 2025.
- A full application package (8-10 pages) that will be requested from PIs whose LOIs describe projects that fit well with the Sanders TDI mission.
- Review of the application by the Sanders TDI Small Molecule Scientific Advisory Board.